Volume 23 Issue 12
Dec.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(12): 2076-2079
XU Jie, HUANG Dongdong, ZHAO Hui, MENG Fangfang, XU Benyong, MA Qiang, ZHAO Qinhua, WU Wenhui. Study on levosimendan in the treatment of patients with chronic thromboembolic pulmonary hypertension complicated with right heart failure[J]. Chinese Journal of General Practice, 2025, 23(12): 2076-2079. doi: 10.16766/j.cnki.issn.1674-4152.004295
Citation: XU Jie, HUANG Dongdong, ZHAO Hui, MENG Fangfang, XU Benyong, MA Qiang, ZHAO Qinhua, WU Wenhui. Study on levosimendan in the treatment of patients with chronic thromboembolic pulmonary hypertension complicated with right heart failure[J]. Chinese Journal of General Practice, 2025, 23(12): 2076-2079. doi: 10.16766/j.cnki.issn.1674-4152.004295
shu

Study on levosimendan in the treatment of patients with chronic thromboembolic pulmonary hypertension complicated with right heart failure

doi: 10.16766/j.cnki.issn.1674-4152.004295
  • 1.

    Department of Cardiology, Lianyungang Municipal Oriental Hospital, Lianyungang, Jiangsu 222042, China

Funds:

 2023YFC2509500

 22ZR1452400

 22PJD064

 20204Y0384

 FKLY20005

 fk18003

 2021LY0415

  • Received Date: 2024-09-16
    Available Online: 2026-03-13
    Abstract
  •   Objective  To observe the effect and drug safety of levosimendan on improving the right heart function in patients with chronic thromboembolic pulmonary hypertension (CTEPH) complicated by right heart failure (RHF).  Methods  Fifty-four patients diagnosed with CTEPH and RHF, admitted to the Department of Pulmonary Circulation in Shanghai Pulmonary Hospital Affiliated to Tongji University from June 2021 to December 2022 were prospectively included and randomly divided into two groups: levosimendan group (n=28) and milrinone group (n=26). Both groups received standard treatment for CTEPH and heart failure, including pulmonary hypertension targeted drugs, diuretics, and so on. In addition, levosimendan was administered intravenously in levosimendan group; milrinone was administered in the milrinone group. Key parameters such as blood pressure, heart rate, and N-terminal B-type natriuretic peptide (NT-proBNP), and changes in right heart function and structure were recorded before and 7 days after treatment.  Results  After treatment, the levosimendan group showed significantly reductions in NT-proBNP levels and total bilirubin levels (P < 0.05). Furthermore, improvements in arterial oxygen saturaion and echocardiographic parameters such as pulmonary artery systolic pressure, right atrial diameter, right ventricular end-diastolic diameter, tricuspid annular plane systolic excursion (TAPSE), and S' wave were observed. The increase in TAPSE after treatment was not significant in the milrinone group (P>0.05), while it was significantly elevated in the levosimendan group (P < 0.05). Both drugs were associated with reductions in systemic blood pressure, but no clinical symptoms due to hypotension were observed, and there were no significant impacts on liver and kidney function (P>0.05).  Conclusion  Levosimendan effectively reduces NT-proBNP and bilirubin levels, improves TAPSE, and enhances right heart function in patients with CTEPH and RHF, and demonstrating good safety.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1): 11-51.

    Pulmonary Embolism and Pulmonary Vascular Diseases Group, Respiratory Medicine Branch of Chinese Medical Association, Pulmonary Embolism and Pulmonary Vascular Diseases Working Committee, Respiratory Physicians Branch of Chinese Medical Association, National Pulmonary Embolism and Pulmonary Vascular Diseases Prevention and Treatment Collaboration Group, et al. Guidelines for the diagnosis and treatment of pulmonary arterial hypertension in China (2021 version)[J]. National Medical Journal of China, 2021, 101(1): 11-51.
    [2]
    陶学娇, 卢均坤, 陈嘉辉, 高玉进. FIB-4、sST2水平与心力衰竭及其严重程度的相关性分析[J]. 新医学, 2023, 54(8): 569-573.

    TAO X J, LU J K, CHEN J H, et al. Correlation analysis of FIB-4 and sST2 levels with heart failure and its severity[J]. New Medicine, 2023, 54(8): 569-573.
    [3]
    伍鑫, 王文艳, 徐芸, 等. 左西孟旦联合重组人脑利钠肽对急性失代偿性射血分数减低的心力衰竭患者的影响[J]. 中华老年心脑血管病杂志, 2023, 25(5): 465-468.

    WU X, WANG W Y, XU Y, et al. Effect of levosimendan combined with recombinant human brain natriuretic peptide on patients with acute decompensated heart failure with reduced ejection fraction[J]. Chinese Journal of Geriatric Heart Brain and Vascular Diseases, 2023, 25(5): 465-468.
    [4]
    晏露, 赵智慧, 赵青, 等. 左西孟旦治疗重症肺动脉高压合并右心衰竭患者的有效性和安全性观察[J]. 中国循环杂志, 2022, 37(3): 239-242.

    YAN L, ZHAO Z H, ZHAO Q, et al. Observation on the efficacy and safety of levosimendan in the treatment of patients with severe pulmonary arterial hypertension complicated with right heart failure[J]. Chinese Circulation Journal, 2022, 37(3): 239-242.
    [5]
    李令娟, 刘冬, 王卫娟, 王宏伟, 孙美娜. 血液Lp-PLA2、SAA、NT-proBNP对急性心肌梗死患者院内早期心衰的评估价值[J]. 贵州医科大学学报, 2023, 48(9): 1066-1072.

    LI L J, LIU D, WANG W J, et al. The evaluation value of blood Lp-PLA2, SAA and NTproBNP in the early post-hospitalization heart failure of patients with acute myocardial infarction[J]. Journal of Guizhou Medical University, 2023, 48(9): 1066-1072.
    [6]
    韦斌, 张朝勇, 邓燕, 等. 间断重复应用左西孟旦治疗肺动脉高压右心衰竭的临床观察[J]. 中国药房, 2022, 33(14): 1754-1758.

    WEI B, ZHANG C Y, DENG Y, et al. Clinical observation of intermittent repeated application of levosimendan in the treatment of right heart failure due to pulmonary arterial hypertension[J]. China Pharmacy, 2022, 33(14): 1754-1758.
    [7]
    高璐阳, 罗勤, 赵智慧, 等. 球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压新进展[J]. 协和医学杂志, 2023, 14(5): 1060-1066.

    GAO L Y, LUO Q, ZHAO Z H, et al. New progress in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1060-1066.
    [8]
    茅焕豪, 叶剑飞, 郑伟峰, 等. 左西孟旦联合冻干重组人脑利钠肽对缺血性心肌病患者心室重构改善作用的研究[J]. 中华全科医学, 2021, 19(11): 1861-1863, 1950. doi: 10.16766/j.cnki.issn.1674-4152.002186

    MAO H H, YE J F, ZHENG W F, et al. Study on the improvement effect of levosimendan combined with lyophilized recombinant human brain natriuretic peptide on ventricular remodeling in patients with ischemic cardiomyopathy[J]. Chinese Journal of General Practice, 2021, 19(11): 1861-1863, 1950. doi: 10.16766/j.cnki.issn.1674-4152.002186
    [9]
    MILWIDSKY A, FRYDMAN S, LAUFER-PERL M, et al. Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients[J]. ESC Heart Fail, 2022, 9(2): 1487-1491. doi: 10.1002/ehf2.13807
    [10]
    朱子雄, 李学文. 左西孟旦治疗心力衰竭研究进展[J]. 中西医结合心脑血管病杂志, 2023, 21(5): 863-865.

    ZHU Z X, LI X W. Research progress of levosimendan in the treatment of heart failure[J]. Chinese Journal of Integrated Traditional and Western Medicine on Cardio-Cerebrovascular Disease, 2023, 21(5): 863-865.
    [11]
    JIANG R, ZHAO Q H, WU W H, et al. Efficacy and safety of a calcium sen-sitizer, levosimendan, in patients with right heart failure due to pulmonary hyp-ertension[J]. Clin Respir J, 2018, 12(4): 1518-1525. doi: 10.1111/crj.12699
    [12]
    QU C, FENG W, ZHAO Q, et al. Effect of levosimendan on acute decompensated right heart failure in patients with connective tissue disease-associated pulmonary arterial hypertension[J]. Front Med (Lausanne), 2022, 9: 778620. DOI: 10.3389/fmed.2022.778620.
    [13]
    NAG P, CHOWDHURY S R, BEHERA S K, et al. Levosimendan or milrinone for ventricular septal defect repair with pulmonary arterial hypertension[J]. J Cardiothorac Vasc Anesth, 2023, 37(6): 972-979. doi: 10.1053/j.jvca.2023.01.032
    [14]
    SCHROEDER L, HOLCHER S, LEYENS J, et al. Evaluation of levosimendan as treatment option in a large case-series of preterm infants with cardiac dysfunction and pulmonary hypertension[J]. Eur J Pediatr, 2023, 182(7): 3165-3174. doi: 10.1007/s00431-023-04971-9
    [15]
    CHOLLEY B, BOJAN M, GUILLON B, et al. Overview of the current use of levosimendan in France: a prospective observational cohort study[J]. Ann Intensive Care, 2023, 13(1): 69. DOI: 10.1186/s13613-023-01164-3.
    [16]
    何潇. 不同剂量左西孟旦治疗老年重症心力衰竭的临床研究[J]. 中国现代医学杂志, 2021, 31(10): 24-28.

    HE X. Clinical study of different doses of levosimendan in the treatment of elderly patients with severe heart failure[J]. China Journal of Modern Medicine, 2021, 31(10): 24-28.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(7)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (14) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return